Clinical Trial

Validation of TAD in HER-2 with More Than 2 Lymph Nodes

Study acronym: DAD-HER2
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main objective of the study is to validate the DAT technique in patients with Her2-positive breast cancer who have more than two positive axillary lymph nodes at diagnosis. After receiving adequate oncological treatment and axillary assessment by ultrasound for complete radiological response, DAT and Berg level I and II lymphadenectomy will be performed to assess false negatives and positives, as well as their sensitivity and specificity.
Trial Details
NCT Number NCT06821490
Lead Sponsor Fundación para la Investigación del Hospital Clínico de Valencia
Conditions Breast Carcinoma Metastatic in Lymph Node, HER2 Positive Breast Carcinoma
Enrollment 21 participants
Start Date 2024-06-30
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-02-12